Publication | Open Access

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

Escalation TrialOncologyPancreatic CancerGastrointestinal OncologyMedicinePharmacotherapyMetastatic Pancreatic CancerCancer TreatmentPharmacologyRadiation OncologyChemotherapy-naive Patients